3 Amendments of György HÖLVÉNYI related to 2021/2007(INI)
Amendment 31 #
Draft opinion
Paragraph 4 a (new)
Paragraph 4 a (new)
4 a. Notes that the lack of access to affordable vaccines is still a major challenge in developing countries, considers that, therefore, investments in local manufacturing capacities, training of health professionals and the development of storage and roll-out capacities should be priorities in the EU external response to COVID-19;
Amendment 36 #
Draft opinion
Paragraph 5
Paragraph 5
5. Welcomes, as a positive step, the recently announced US support for a proposal to temporarily waive certain provis that least-developed countries already enjoy a waiver, granted until 1January 2033, regarding the implementations of the Agreement on Trade- Related Aspects of Intellectual Property Rights for the prevention, containment and treatment of COVID-19; urges the Commission, therefore, to follow through on its promise to engage in active and constructive text-based negotiations at World Trade Organization level.provisions on pharmaceuticals, and is convinced that suggestions of removing IP protections for vaccines would not remedy the existing shortage of vaccines; urges therefore the Commission, in cooperation with the WTO , to follow through on its promise to engage in active and constructive text-based negotiations at World Trade Organization to work on incentivising and supporting the scaling up of production capacities for vaccines in developing countries and incentivise voluntary licensing agreements as well as to launch a dialogue about existing obstacles to voluntary licensing and how to overcome them;
Amendment 41 #
5 a. Strongly supports effective measures to address the shortage of vaccines against COVID-19, especially in developing countries, and therefore supports the Commission and the Member States in their efforts to push non-EU countries to lift existing export bans and to step up the donation of vaccines; calls on the Commission and the Member States to further increase their efforts to support technology transfer and voluntary licensing for intellectual property rights to treat endemic or pandemic infectious diseases in the world population;